Proxy Results (Form 8-K)

On June 11, 2026, Ocugen, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") virtually at 8:00 a.m. ET. At the Annual Meeting, a total of 139,628,075 shares of the Common Stock were represented virtually or by proxy.

The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting on June 11, 2026:

(a) Proposal 1 - Election of Two Class III Directors. The stockholders elected Kirsten Castillo, MBA, and Satish Chandran, Ph.D. to the Board of Directors of the Company (the "Board") to serve as a director until the 2029 Annual Meeting of Stockholders and until their respective successor, if any, is elected and qualified, or until their earlier death, resignation, retirement, disqualification, or other removal, as follows:

(b) Proposal 2 - Ratification of Independent Registered Public Accountant. The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year, as follows:

(c) Proposal 3 - Approval, on an advisory basis, of the compensation of the Company's named executive officers. The stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers, as follows:

(d) Proposal 4 - Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers. The stockholders voted to approve, on an advisory basis, a preferred frequency of "one year" for future advisory votes on the compensation of the Company's named executive officers, as follows:

Based on the results of the vote, the Board has determined to hold an advisory vote on the compensation of the named executive officers of the Company every year until the next required advisory vote on the frequency of future advisory votes on named executive officer compensation.

As previously reported, effective May 8, 2026, the Company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer. The Company appointed Dr. Genead as Chief Medical Officer effective as of June 11, 2026.